KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.
Korean AKI drug at Series A — therapeutic at the same stage.
Evidence from the records
- “Series A”
- “Drug for acute kidney injury”
- “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
- Intro path
- Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Kaitai Capital).
- First step
- Qualify via Pleryon.